These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 35089397)
1. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). Nakase H; Hayashi Y; Hirayama D; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Abukawa D; Hisamatsu T; J Gastroenterol; 2022 Mar; 57(3):174-184. PubMed ID: 35089397 [TBL] [Abstract][Full Text] [Related]
2. Final Analysis of COVID-19 Patients With Inflammatory Bowel Disease in Japan (J-COSMOS): A Multicenter Registry Cohort Study. Nakase H; Hayashi Y; Yokoyama Y; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Abukawa D; Hisamatsu T; Gastro Hep Adv; 2023; 2(8):1056-1065. PubMed ID: 39131552 [TBL] [Abstract][Full Text] [Related]
3. Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Bezzio C; Armuzzi A; Furfaro F; Ardizzone S; Milla M; Carparelli S; Orlando A; Caprioli FA; Castiglione F; Viganò C; Ribaldone DG; Zingone F; Monterubbianesi R; Imperatore N; Festa S; Daperno M; Scucchi L; Ferronato A; Pastorelli L; Balestrieri P; Ricci C; Cappello M; Felice C; Fiorino G; Saibeni S; Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1432-1441. PubMed ID: 34694009 [TBL] [Abstract][Full Text] [Related]
4. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research. Nakase H; Matsumoto T; Matsuura M; Iijima H; Matsuoka K; Ohmiya N; Ishihara S; Hirai F; Wagatsuma K; Yokoyama Y; Hisamatsu T Digestion; 2021; 102(5):814-822. PubMed ID: 32892197 [TBL] [Abstract][Full Text] [Related]
5. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. Guerra I; Algaba A; Jiménez L; Mar Aller M; Garza D; Bonillo D; Molina Esteban LM; Bermejo F Inflamm Bowel Dis; 2021 Jan; 27(1):25-33. PubMed ID: 32830267 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications. Sima AR; Saberzadeh-Ardestani B; Vahedi H; Fakheri H; Mansour-Ghanaei F; Maleki I; Nasseri-Moghaddam S; Vosoghinia H; Ghadir MR; Hormati A; Kasaeian A; Radmard AR; Khosravi B; Malekzadeh M; Alatab S; Sadeghi A; Aminisani N; Poustchi H; Gonoudi E; Anushiravani A; Rayatpisheh M; Colombel JF; Ungaro RC; Malekzadeh R Arch Iran Med; 2022 Jan; 25(1):17-25. PubMed ID: 35128908 [TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Wetwittayakhlang P; Albader F; Golovics PA; Hahn GD; Bessissow T; Bitton A; Afif W; Wild G; Lakatos PL Can J Gastroenterol Hepatol; 2021; 2021():7591141. PubMed ID: 34858891 [TBL] [Abstract][Full Text] [Related]
8. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease. De Nicolò A; Cusato J; Bezzio C; Saibeni S; Vernero M; Disabato M; Caviglia GP; Ianniello A; Manca A; D'Avolio A; Ribaldone DG Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615826 [TBL] [Abstract][Full Text] [Related]
9. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Brenner EJ; Pigneur B; Focht G; Zhang X; Ungaro RC; Colombel JF; Turner D; Kappelman MD; Ruemmele FM Clin Gastroenterol Hepatol; 2021 Feb; 19(2):394-396.e5. PubMed ID: 33059040 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 in IBD: The experience of a single tertiary IBD center. Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910 [TBL] [Abstract][Full Text] [Related]
11. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2. Łodyga M; Maciejewska K; Eder P; Waszak K; Stawczyk-Eder K; Michalak M; Dobrowolska A; Wiśniewska-Jarosińska M; Gąsiorowska A; Cicha M; Wierzba W; Rydzewska G Pol Arch Intern Med; 2021 Mar; 131(3):226-232. PubMed ID: 33544564 [TBL] [Abstract][Full Text] [Related]
12. Effect of inflammatory bowel disease and related medications on COVID-19 incidence, disease severity, and outcome: the Israeli experience. Richter V; Bermont A; Cohen DL; Broide E; Shirin H Eur J Gastroenterol Hepatol; 2022 Mar; 34(3):267-273. PubMed ID: 34191758 [TBL] [Abstract][Full Text] [Related]
13. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Gilissen LPL; Heinen SGH; Rijpma-Jacobs L; Schoon E; Schreuder RM; Wensing AM; van der Ende-van Loon MCM; Bloemen JG; Stapelbroek JM; Stronkhorst A Clin Exp Med; 2022 Aug; 22(3):465-476. PubMed ID: 34542781 [TBL] [Abstract][Full Text] [Related]
14. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. Creemers RH; Rezazadeh Ardabili A; Jonkers DM; Leers MPG; Romberg-Camps MJ; Pierik MJ; van Bodegraven AA PLoS One; 2021; 16(10):e0258271. PubMed ID: 34610041 [TBL] [Abstract][Full Text] [Related]
15. Safety, hesitancy of coronavirus disease 2019 vaccination and pandemic burden in patients with inflammatory bowel disease: data of a national study (ESCAPE-IBD). Principi M; Macaluso FS; Todeschini A; Facciotti F; Contaldo A; Castiglione F; Nardone OM; Spagnuolo R; Doldo P; Riguccio G; Conforti FS; Viganò C; Ascolani M; Fiorino G; Correale C; Bodini G; Milla M; Scardino G; Vernero M; Desideri F; Caprioli F; Mannino M; Rizzo G; Orlando A; Eur J Gastroenterol Hepatol; 2023 Jun; 35(6):629-634. PubMed ID: 37115976 [TBL] [Abstract][Full Text] [Related]
16. Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients. Waggershauser CH; Tillack-Schreiber C; Weyh P; Alt E; Siegmund T; Berchthold-Benchieb C; Szokodi D; Schnitzler F; Ochsenkühn T Can J Gastroenterol Hepatol; 2022; 2022():3469789. PubMed ID: 36060521 [TBL] [Abstract][Full Text] [Related]
17. Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. Ricciuto A; Lamb CA; Benchimol EI; Walker GJ; Kennedy NA; Kuenzig ME; Kaplan GG; Kappelman MD; Ungaro RC; Colombel JF; Brenner EJ; Agrawal M; Reinisch W; Griffiths AM; Sebastian S J Crohns Colitis; 2022 May; 16(4):591-600. PubMed ID: 34570886 [TBL] [Abstract][Full Text] [Related]
18. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. Ardizzone S; Ferretti F; Monico MC; Carvalhas Gabrielli AM; Carmagnola S; Bezzio C; Saibeni S; Bosani M; Caprioli F; Mazza S; Casini V; Cortelezzi CC; Parravicini M; Cassinotti A; Cosimo P; Indriolo A; Di Sabatino A; Lenti MV; Pastorelli L; Conforti F; Ricci C; Sarzi-Puttini P; Vecchi M; Maconi G J Gastroenterol Hepatol; 2021 Nov; 36(11):3050-3055. PubMed ID: 34159648 [TBL] [Abstract][Full Text] [Related]
19. [The gastrointestinal effects of COVID–19 infection during childhood and among the children affected with inflammatory bowel disease]. Tóbi L; Prehoda B; Balogh A; Dezsőfi-Gottl A; Cseh Á Orv Hetil; 2022 Feb; 163(6):214-221. PubMed ID: 35124570 [TBL] [Abstract][Full Text] [Related]
20. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID]. Lee YJ; Kim SE; Park YE; Chang JY; Song HJ; Kim DH; Yang YJ; Kim BC; Lee JG; Yang HC; Choi M; Myung SJ; Korean J Gastroenterol; 2021 Aug; 78(2):117-128. PubMed ID: 34446634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]